Home › Phenylketonuria › Pennsylvania
Phenylketonuria clinical trials in Pennsylvania
8 studies for Phenylketonuria are looking for participants at sites in Pennsylvania.
Cities in Pennsylvania
A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-181 in Subjects With Phenylketonuria
- UPMC Children's Hospital of Pittsburgh, Pittsburgh
RecruitingPhase 1
Ages 18 to 69 · All sexes · Updated Sep 28, 2026 · NCT07241234A Study of MZE782 in Adults With PKU
- Clinic for Special Children, Gordonville
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Aug 20, 2026 · NCT07694440AAV Gene Therapy Clinical Study in Adult Classic PKU (PHEdom)
- University of Pittsburgh Medical Center, Pittsburgh
RecruitingPhase 1/2
Ages 18 to 55 · All sexes · Updated Aug 18, 2026 · NCT06332807A Study of JNT-517 in Participants With Phenylketonuria (PKU)
- University of Pittsburgh Medical Center (UPMC) - Children's Hospital of Pittsburgh, Pittsburgh
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Jul 8, 2026 · NCT06971731Immune Modulation During Palynziq® Treatment in Adults (IMPALA)
- University of Pittsburgh Medical Center (UPMC) - Children's Hospital of Pittsburgh, Philadelphia
RecruitingPhase 4
Ages 18 to 65 · All sexes · Updated Jun 17, 2026 · NCT07477691A Long-Term Study of JNT-517 in Participants With Phenylketonuria
- University of Pittsburgh Medical Center (UPMC) - Children's Hospital of Pittsburgh, Pittsburgh
RecruitingPhase 3
Ages 4 and older · All sexes · Updated May 1, 2026 · NCT06628128A Long-term, Post-marketing Safety Study of Palynziq in Patients With PKU (PALace)
- University of Pittsburgh Medical Center, Pittsburgh
RecruitingObservational study
All ages · All sexes · Updated Mar 25, 2026 · NCT05813678A Long Term, Post-marketing Study of Immune Response in Patients Receiving Palynziq Treatment for PKU (PALisade)
- University of Pittsburgh Medical Center, Pittsburgh
RecruitingObservational study
All ages · All sexes · Updated Mar 24, 2026 · NCT06305234From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.